Dr. Reddy's Laboratories Limited — Others, 14-04-2025: Rumour Verification - Regulation 30(11)

Dr. Reddy's Laboratories has announced a board meeting to address recent claims regarding a 25% reduction in workforce costs linked to margin pressures from Revlimid. The company has categorically denied these assertions as factually incorrect, stating there are no events warranting disclosure under SEBI regulations. This clarification aims to reassure investors about the company's operational stability amid market speculation. The denial of the claims may provide a positive outlook for investor sentiment, alleviating concerns around cost-cutting measures and potential impacts on workforce morale and productivity.